421592-45-2

Upstream product

• 4539-78-0 2,3,4-tri-O-benzyl-D-glucopyranosideuronic acid benzyl ester 
• 152595-73-8 1,2-dihydro-4-(ethylphenyl)methyl-5-trifluoromethyl-3H-pyrazol-3-one 
• 152595-73-8 1,2-dihydro-4-[(4-ethylphenyl)-methyl]-5-(trifluoromethyl)-3H-pyrazole-3-one 
• 125474-13-7 benzyl 2,3,4-tri-O-benzyl-α-D-glucopyranuronate 

Relevant academic research and scientific papers

Pyrazole-O-glucosides as novel Na+-glucose cotransporter (SGLT) inhibitors

O-glucuronides and O-glucosides of a series of pyrazoles analogues were synthesized and evaluated for their SGLT inhibitory activity in brush border membrane vehicles (BBMVs) of rat kidney. O-glucosides of certain pyrazole analogues inhibited the transport of [14C]-glucose in BBMVs, and induced glucosuria in Wistar rats by intravenous injection.

PREVENTIVE/REMEDY FOR DIABETES

The invention provides a prophylactic and therapeutic agent of diabetes mellitus, including a combination of an inhibitor of renal glucose reabsorption and a hypoglycemic agent. In accordance with the invention, hyperglycemia after meals, between meals and during fasting can be ameliorated. More specifically, in accordance with the invention, a therapeutic effect of diabetes mellitus as never been obtained by the hypoglycemic agents of the related art can be achieved.

Pyrazole derivatives and diabetic medicine containing them

The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine.